Federal contract award
75F40121C00194
DEVELOPMENT AND MAINTENANCE OF FDA-ARGOS 2 UNIVERSAL CLOSED SYSTEMS FOR PATHOGEN REDUCTION IN DONATED WHOLE BLOOD UNITS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541990 — All Other Professional, Scientific, and Technical Services |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST NO FEE |
| Obligations | $6.7M |
| Current contract value | $6.7M |
| Potential contract value / ceiling | $6.7M |
| Start date | Sep 27, 2021 |
| Current end date | Sep 26, 2023 |
| Potential end date | Mar 26, 2025 |
| Latest award activity | Aug 25, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 8 of 8 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 25, 2026 | P00007 | $-5.9M | NO COST MODIFICATION TO CHANGE THE PERIOD OF PERFORMANCE END DATE TO MARCH 26, 2025. |
| Sep 18, 2024 | P00006 | $0 | NO COST MODIFICATION TO CHANGE THE PERIOD OF PERFORMANCE END DATE TO MARCH 26, 2025. |
| Aug 29, 2023 | P00005 | $5.5M | THE PURPOSE OF THIS BILATERAL MODIFICATION IS TO EXERCISE OPTION PERIOD TWO (2) |
| May 16, 2023 | P00004 | $0 | UNIVERSAL CLOSED SYSTEMS FOR PATHOGEN REDUCTION IN DONATED WHOLE BLOOD UNITSWHOLE BLOOD UNITS |
| Feb 8, 2023 | P00003 | $0 | UNIVERSAL CLOSED SYSTEMS FOR PATHOGEN REDUCTION IN DONATED WHOLE BLOOD UNITSWHOLE BLOOD UNITS |
| Sep 22, 2022 | P00002 | $4.8M | UNIVERSAL CLOSED SYSTEMS FOR PATHOGEN REDUCTION IN DONATED WHOLE BLOOD UNITSWHOLE BLOOD UNITS |
| Nov 30, 2021 | P00001 | $0 | EO14042 DEVELOPMENT AND MAINTENANCE OF FDA-ARGOS 2 UNIVERSAL CLOSED SYSTEMS FOR PATHOGEN REDUCTION IN DONATED WHOLE BLOOD UNITS |
| Sep 27, 2021 | 0 | $2.3M | DEVELOPMENT AND MAINTENANCE OF FDA-ARGOS 2 UNIVERSAL CLOSED SYSTEMS FOR PATHOGEN REDUCTION IN DONATED WHOLE BLOOD UNITS |
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 2404028639 | Source | May 26, 2021 |
| Robert Maydwell | Contact | Robert.Maydwell@fda.hhs.gov 301-348-1814 | Source | May 26, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 2404028639 | Source | May 26, 2021 |
| Anthony S. Wimbush | Contact | anthony.wimbush@fda.hhs.gov 2404027628 | Source | May 26, 2021 |
| Kimberly DeLong | Contact | kimberly.delong@fda.hhs.gov 2404028639 | Source | Jan 28, 2021 |
| Anthony S. Wimbush | Contact | anthony.wimbush@fda.hhs.gov 2404027628 | Source | Jan 28, 2021 |
| Benjamin Golway | Contact | Benjamin.Golway@fda.hhs.gov 3018374464 | Source | Nov 20, 2020 |
| Anthony S. Wimbush | Contact | anthony.wimbush@fda.hhs.gov 2404027628 | Source | Nov 20, 2020 |
Research next steps
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.